Enanta Pharmaceuticals Appoints Mark G. Foletta to Board of Directors
June 29, 2020 at 07:00 am EDT
Share
Enanta Pharmaceuticals, Inc. announced the appointment of Mark G. Foletta to its Board of Directors. Mr. Foletta will also serve as the Chair of the Audit Committee and will be a member of the Nominating and Corporate Governance Committee. The appointment of Mr. Foletta increases the number of Enanta Directors to seven. Most recently, he was Executive Vice President and Chief Financial Officer of Tocagen, a clinical-stage biopharmaceutical company focused on advancing a cancer-selective gene therapy platform, prior to its merger with Forte Biosciences. Prior to Tocagen, Mr. Foletta was Chief Financial Officer of Biocept, Inc. and served as Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc., where he helped drive the evolution of the company from a research and development organization to a fully integrated biopharmaceutical company. Mr. Foletta has held other management positions including Senior Vice President, Chief Financial Officer and Corporate Secretary of Intermark, Inc. and Triton Group Ltd. Mr. Foletta currently serves as the Lead Independent Director of DexCom, Inc. and is Chairman of the Audit Committee of AMN Healthcare Services, Inc. He has previously served on the Boards of Directors and as Audit Committee Chair of Regulus Therapeutics, Inc., Ambit Biosciences, Inc. and Anadys Pharmaceuticals, Inc.Mr. Foletta received a B.A. in Business Economics from the University of California, Santa Barbara and is a member of the Corporate Directors Forum.
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on indications in virology and immunology. The Company's research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). The Company discovered glecaprevir, the second of two protease inhibitors discovered and developed through its collaboration with AbbVie for the treatment of chronic infection with hepatitis C virus (HCV). Glecaprevir is co-formulated as part of AbbVie's direct-acting antiviral (DAA) combination treatment for HCV, which is marketed under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). Its research and development programs are in virology, namely RSV, SARS-CoV-2 and hepatitis B virus. The Company has a research program targeting development of single agents with broader spectrum antiviral activity against both RSV and human metapneumovirus (hMPV).